BioCryst Pharmaceuticals, Inc. (BCRX)
BCRX Stock Price Chart
Explore BioCryst Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze BCRX price movements and trends.
BCRX Company Profile
Discover essential business fundamentals and corporate details for BioCryst Pharmaceuticals, Inc. (BCRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Mar 1994
Employees
580.00
Website
https://www.biocryst.comCEO
Charles K. Gayer
Description
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
BCRX Financial Timeline
Browse a chronological timeline of BioCryst Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Aug 2026
EPS estimate is $0.14, while revenue estimate is $183.28m.
Earnings released on 6 May 2026
EPS came in at -$2.98 falling short of the estimated $0.06 by -5.07k%, while revenue for the quarter reached $156.41m , beating expectations by +3.50%.
Earnings released on 26 Feb 2026
EPS came in at $1.12 surpassing the estimated $0.07 by +1.50k%, while revenue for the quarter reached $406.56m , beating expectations by +168.66%.
Earnings released on 3 Nov 2025
EPS came in at $0.06 falling short of the estimated $0.07 by -14.29%, while revenue for the quarter reached $159.40m , beating expectations by +5.34%.
Earnings released on 4 Aug 2025
EPS came in at $0.15 surpassing the estimated $0.03 by +400.00%, while revenue for the quarter reached $163.35m , beating expectations by +9.20%.
Earnings released on 5 May 2025
EPS came in at $0.00 surpassing the estimated -$0.07 by +100.21%, while revenue for the quarter reached $145.53m , missing expectations by -2.80%.
Earnings released on 24 Feb 2025
EPS came in at -$0.13 falling short of the estimated -$0.07 by -85.71%, while revenue for the quarter reached $131.53m , beating expectations by +3.87%.
Earnings released on 4 Nov 2024
EPS came in at -$0.07 matching the estimated -$0.07, while revenue for the quarter reached $117.09m , missing expectations by -8.33%.
Earnings released on 5 Aug 2024
EPS came in at -$0.06 surpassing the estimated -$0.19 by +68.42%, while revenue for the quarter reached $109.33m , beating expectations by +11.20%.
Earnings released on 6 May 2024
EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%, while revenue for the quarter reached $92.76m , beating expectations by +8.37%.
Earnings released on 26 Feb 2024
EPS came in at -$0.28 falling short of the estimated -$0.24 by -16.67%, while revenue for the quarter reached $93.40m , beating expectations by +3.77%.
Earnings released on 2 Nov 2023
EPS came in at -$0.19 surpassing the estimated -$0.25 by +24.00%, while revenue for the quarter reached $86.74m , beating expectations by +0.92%.
Earnings released on 3 Aug 2023
EPS came in at -$0.24 surpassing the estimated -$0.25 by +4.00%, while revenue for the quarter reached $82.49m , beating expectations by +1.85%.
Earnings released on 3 May 2023
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%, while revenue for the quarter reached $68.78m , missing expectations by -4.05%.
Earnings released on 21 Feb 2023
EPS came in at -$0.38 falling short of the estimated -$0.19 by -100.00%, while revenue for the quarter reached $79.55m , beating expectations by +5.74%.
Earnings released on 1 Nov 2022
EPS came in at -$0.23 surpassing the estimated -$0.32 by +28.13%, while revenue for the quarter reached $75.83m , beating expectations by +1.40%.
Earnings released on 4 Aug 2022
EPS came in at -$0.32 surpassing the estimated -$0.36 by +11.11%, while revenue for the quarter reached $65.53m , beating expectations by +3.48%.
Earnings released on 5 May 2022
EPS came in at -$0.40 falling short of the estimated -$0.39 by -2.56%, while revenue for the quarter reached $49.92m , missing expectations by -2.80%.
Earnings released on 23 Feb 2022
EPS came in at -$0.40 falling short of the estimated -$0.31 by -29.03%, while revenue for the quarter reached $47.16m , missing expectations by -7.65%.
Earnings released on 3 Nov 2021
EPS came in at -$0.33 falling short of the estimated -$0.30 by -10.00%, while revenue for the quarter reached $40.99m , beating expectations by +1.92%.
Earnings released on 5 Aug 2021
EPS came in at -$0.24 falling short of the estimated -$0.22 by -9.09%, while revenue for the quarter reached $49.96m , beating expectations by +74.26%.
BCRX Stock Performance
Access detailed BCRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
